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  The liver plays a major role in iron homeostasis; thus, in patients with chronic liver disease, iron regulation may 
be disturbed. Higher iron levels are present not only in patients with hereditary hemochromatosis, but also in 
those with alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C viral infection. Chronic liv-
er disease decreases the synthetic functions of the liver, including the production of hepcidin, a key protein in 
iron metabolism. Lower levels of hepcidin result in iron overload, which leads to iron deposits in the liver and 
higher levels of non-transferrin-bound iron in the bloodstream. Iron combined with reactive oxygen species 
leads to an increase in hydroxyl radicals, which are responsible for phospholipid peroxidation, oxidation of ami-
no acid side chains, DNA strain breaks, and protein fragmentation. Iron-induced cellular damage may be pre-
vented by regulating the production of hepcidin or by administering hepcidin agonists. Both of these methods 
have yielded successful results in mouse models.
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Background
According to epidemiological data, the incidence of chronic 
liver disease is increasing [1,2]. Chronic liver disease includes 
various causes of liver failure that lead to progressive destruc-
tion and regeneration of the liver parenchyma, ending in fi-
brosis and cirrhosis. Cirrhosis is the final stage of liver fibro-
sis and often leads to portal hypertension and hepatic failure; 
patients with end-stage cirrhosis often require liver transplan-
tation. Pathologically, cirrhosis disrupts the liver architecture 
and is associated with fibrotic bands, parenchymal nodules, 
and vascular distortion. The most common causes of chronic 
liver disease are metabolic, viral, toxic, and autoimmune [3–5]. 
In recent years, nonalcoholic fatty liver disease (NAFLD), the 
hepatic expression of metabolic syndrome (MS), has reached 
epidemic proportions. Nowadays, with the increasing preva-
lence of obesity, diabetes mellitus, and MS in the general pop-
ulation, NAFLD has become the most common cause of chron-
ic liver disease in Western countries [6]. Contributing factors 
to this may include the increasingly sedentary lifestyle of the 
population and increased consumption of a high-fat diet and 
high fructose corn syrup [5]. However, therapeutic options to 
treat chronic liver disease are limited and new approaches are 
necessary. Recent studies have highlighted the role of iron in 
the pathophysiology of chronic liver disease. Iron accumula-
tion has been noted not only in patients with hereditary he-
mochromatosis (HH), but also in those with acquired metabolic 
disorders and viral infections [7]. Interestingly, iron perturba-
tions are often observed in patients with obesity, insulin resis-
tance (IR), or NAFLD. The peptide hepcidin is produced main-
ly in the liver, although macrophages, pancreatic islet cells, 
and adipose tissue can also excrete it. Hepcidin was recently 
found to be a key regulator of iron metabolism. Thus, it may 
be of great importance in the development of new therapeutic 
approaches for chronic liver disease [8,9]. The present review 
highlights current knowledge about hepatic iron overload sta-
tus in chronic liver diseases, the impact of hepatic iron over-
load on diseases progression, its relevance to hepatocarcino-
genesis, and possible new therapeutic options.
Role of Liver in Iron Metabolism
Iron is an essential micronutrient for the human body. It has 
important roles in oxygen transport, oxidative phosphoryla-
tion, and other enzymatic functions [10,11]. The human body 
has an average of 2–4 g of iron, of which 80% is bound in 
hemoglobin. There is tight control of systemic iron levels by 
means of iron absorption, storage, and recycling. Iron defi-
ciency causes a decrease in hemoglobin production and can 
consequently lead to anemia, while iron overload burdens the 
body and results in excess tissue iron, which can cause cell 
damage [8,12,13].
Dietary iron is in the ferric form and must be reduced by the api-
cal ferric reductase duodenal cytochrome b (DcytB, also known 
as CYBRD1) to ferrous iron for transport into enterocytes via 
the apical iron transporter divalent metal transporter-1 (DMT-
1, also known as SLC11A2). Iron is exported through ferropor-
tin (SLC40A1), which is located on the basolateral side of en-
terocytes. Once in the bloodstream, iron is bound to transferrin 
(TF). Prior to the binding of iron to TF, it is oxidized back to the 
ferric form by the ferroxidases hephaestin (HEPH) and cerulo-
plasmin (CP) [10,12,13]. Most of the transferrin-bound iron is 
used by erythroblasts to synthesize hemoglobin. Aging eryth-
rocytes undergo erythrophagocytosis, during which iron is re-
covered and routed back to circulation via ferroportin [12,13].
Under conditions in which there is excess iron, cells can se-
crete Fe2+ via ferroportin or secrete heme through the puta-
tive heme exporter feline leukemia virus subgroup C cellu-
lar receptor 1 (FLVCR). Cells can also store iron within ferritin. 
Ferritin is a multi-subunit protein that comprises a variable ra-
tio of heavy and light chains, depending on the type of tissue. 
Hepatocytes serve as a major site of ferritin synthesis, which 
is controlled through a posttranscriptional mechanism by the 
iron response element (IRE)/iron regulatory protein (IRP) net-
work. Hypoxia, oxidative stress, IL1, and TNFα also regulate fer-
ritin expression [10,13].
Iron stored within ferritin is thought to be bioavailable; thus, 
hepatocytes have a crucial role in the mobilization of iron to 
satisfy metabolic requirements [10]. The liver produces the ma-
jority of proteins involved in iron metabolism, including hep-
cidin and transferrin. The main characteristic of transferrin is 
its ability to reversibly bind iron, which allows it to be a cellu-
lar iron donor or iron acceptor [10,12].
Hepcidin is an antimicrobial peptide with a key role in iron me-
tabolism. Its expression is regulated by the bone morphoge-
netic protein (BMP) and JAK2/STAT3 signaling pathways. The 
level of iron in the bloodstream serves as a stimulus for hep-
cidin synthesis. Hepcidin regulates iron delivery via ferropor-
tin. Once it binds to the cell, hepcidin triggers ferroportin deg-
radation by endocytosis and proteolysis of the ligand-receptor 
complex. This results in restriction of iron flow into the plas-
ma and blockage of dietary iron absorption, resulting in hy-
poferremia [14–17].
Disruptions in the BMP signaling pathway result in lower hep-
cidin levels and, consequently, iron overload. BMP binds to a 
BMP receptor complex and activates the SMAD signaling path-
way [10,17]. Research in a mouse model showed that BMP6, 
produced in sinusoidal endothelial cells, has a crucial role in 
maintaining iron metabolism, which cannot be compensated 
for by other BMPs [17].
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Hepatic hemojuvelin (HJV, also known as HFE2) is a corecep-
tor for BMP6 and interacts with neogenin to induce hepcidin 
expression. Hemojuvelin is also synthesized in skeletal and 
heart muscles and can be released into the bloodstream as 
soluble HJV. It is still unclear if soluble HJV suppresses hepci-
din expression by taking the place of hepatic HJV and bind-
ing to BMP6. Recently, 2 specific BMP type I receptors, ALK2 
(ACVR1) and ALK3 (BMPR1A), were identified as important for 
hepcidin regulation [16–18].
Researchers do not yet know definitively how hereditary he-
mochromatosis protein (HFE) and transferrin receptor 2 (TFR2) 
regulate iron homeostasis. A new hypothesis suggests that 
HFE and TFR2 interact with HJV, particularly under conditions 
in which there is high transferrin saturation, and that this 
complex facilitates hepcidin expression induced by HJV [18].
Matriptase-2 (MT2) is a membrane serine protease encoded 
by the gene TMPRSS6 and found mainly in the liver. It releas-
es HJV from hepatocytes; by doing so, it lowers the ability of 
HJV to act as a coreceptor. Thus, MT2 is the key suppressor of 
hepcidin expression [10,16,18].
Hypoxia and erythropoietic activity also suppress hepcidin ex-
pression. During tissue hypoxia, hypoxia inducible factors-1 
and -2 (HIF-1 and HIF-2) activate a variety of genes involved in 
hypoxia adaptation. It remains unknown whether hepcidin re-
lease is suppressed directly by HIF-1 and HIF-2 or if it depends 
upon increased erythropoietic activity [16,18,19].
During inflammation, there is an increase in hepcidin tran-
scription mediated by IL6. Binding of IL6 to its receptors acti-
vates the STAT pathway, which works in synergy with the BMP 
pathway to stimulate hepcidin synthesis. Other cytokines, in-
cluding IL22 and oncostatin M, are also suspected of having 
the same effect [16,20].
Changes in Iron Metabolism in Patients with 
Chronic Liver Disease
Considering the critical role played by the liver in iron metab-
olism, it follows that liver diseases affect iron homeostasis. 
Iron accumulation has been noted not only in patients with 
HH, but also in those with NAFLD, alcoholic liver disease (ALD), 
and hepatitis C virus (HCV) infection [21–23].
Hemochromatosis
HH is a genetic disorder that causes dysregulation of hepcidin 
homeostasis and, consequently, iron overload (24). There are 
4 types of HH. Type 1 is the most common. It is caused by a 
missense mutation of cysteine 282 to tyrosine (Cys282Tyr) in 
the HFE gene (HFE). HFE binding to TFR1 (also known as TFRC) 
is thought to be the mechanism by which HFE blocks hepci-
din expression. This binding is increased in patients with the 
type 1 HFE mutation, enabling HFE to interact with TFR2 and 
thus facilitate hepcidin expression. Juvenile hemochromatosis, 
or HH types 2a and 2b, is a rare condition; mutations in HFE2 
and HAMP, in types 2a and 2b, respectively, result in almost 
complete loss of hepcidin synthesis. Type 3 hemochromato-
sis is characterized by TFR2 mutations, and type 4 involves 
mutation of SLC40A1, which encodes the iron exporter fer-
roportin. The severity of iron overload depends upon the lev-
el of hepcidin deficiency. Iron hyperabsorption and rapid iron 
release from macrophages can occur. As the result of large 
iron flux, the iron-binding capacity of transferrin is exceeded, 
causing nontransferrin-bound iron (NTBI) levels to rise in the 
bloodstream. NTBI accumulates in the liver and other paren-
chyma [8,10,24,25].
Alcoholic liver disease
Alcoholic liver disease is one of the major liver diseases in the 
developed countries and is characterized by hepatic iron over-
load in approximately 50% of all patients. According to the lit-
erature, chronic alcohol consumption in moderate to exces-
sive amounts is associated with elevation of serum ferritin 
concentration and transferrin saturation, and can result in in-
creased hepatic iron stores. Additionally, increased intestinal 
iron absorption has been documented in patients with ALD. 
Iron and ethanol each cause oxidative stress and lipid perox-
idation and the cumulative effects of ethanol and iron on liv-
er cell damage, in patients with ALD, exacerbate liver injury. 
Therefore, iron overload is an independent factor of disease 
progression in hepatocellular carcinoma and it determines pa-
tient survival [26,27].
ALD includes a spectrum of liver disorders ranging from fatty 
liver and hepatic inflammation and necrosis (alcoholic hepa-
titis) to progressive fibrosis (alcoholic cirrhosis) [28]. Serum 
iron markers are elevated in alcohol drinkers from an early 
age [11]. The characteristics of iron distribution disorders are 
shown in Table 1. In patients with ALD, ferritin levels are of-
ten markedly elevated, and serum iron and transferrin satu-
ration can also be greatly elevated. Additionally, in these pa-
tients low hepcidin levels are usually found along with iron 
deposition in macrophages. There are 2 opposing, hepcidin-
regulating, stimuli that occur in ALD. On the one hand, alco-
hol-induced endoplasmic reticulum (ER) stress and inflam-
mation leads to hepcidin upregulation, while on the other, 
ethanol downregulates the mRNA- and DNA-binding activity 
of CCAAT/enhancer binding protein (C/EBP), alpha (C/EBPa, 
also known as CEBPA), which is the main transcription factor 
regulating hepcidin expression. According to the literature, the 
down-regulation of hepcidin expression leads to up-regulation 
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of iron transporters expression in the duodenum. This affects 
ferroportin and DMT1 and leads to increased iron absorption in 
the duodenum. These observations could explain iron metab-
olism disturbances in ALD [11,27,28], and were recently con-
firmed by Dostalikova-Cimburova et al. [27] in patients with 
ALD. Alcohol consumption very probably causes suppression of 
hepcidin expression in patients with ALD. Taken together, iron 
overload observed in patients with ALD is mediated by reg-
ulatory mechanisms, and the alcohol-mediated down-regula-
tion of hepcidin synthesis in the liver may be one of the dom-
inant underlying mechanisms of iron overload. Interestingly, 
new reports indicate that the presence of iron may be predic-
tive of death and hepatocellular carcinoma (HCC) development 
in patients with alcoholic cirrhosis [11,28].
Nonalcoholic fatty liver disease
As the prevalence of obesity and MS rises, NAFLD with or with-
out associated MS has become the most prevalent form of 
chronic liver disease. It is commonly considered as a hepatic 
manifestation of MS and is thought to be involved in the patho-
genesis of cardiovascular diseases [11,29,30]. Nonalcoholic ste-
atohepatitis (NASH), a more severe form of NAFLD, is charac-
terized by chronic and progressive liver pathology and may 
lead to fibrosis, liver cirrhosis, end-stage liver disease, and 
hepatocellular carcinoma [5]. Perturbations of iron homeo-
stasis are often seen in NAFLD patients. Characteristic find-
ings in NAFLD patients are elevated iron stores as indicated 
by hyperferritinemia, with normal or mildly elevated transfer-
rin saturation and mostly mild liver iron deposition in liver bi-
opsies (hemosiderosis). Serum ferritin levels range from mild 
elevations to 1000–1500 ng/ml. Its concentrations increase 
with the number of MS components. Transferrin saturation 
is in the upper range or normal or mildly elevated (45–50%) 
(Table 1). On the other hand, in patients with hemochroma-
tosis, high ferritin levels are associated with markedly elevat-
ed transferrin saturation [31]. A recently introduced term, dys-
metabolic or insulin-resistance hepatic iron overload syndrome 
(DIOS or IR-HIO, respectively) has been used in cases of un-
explained hepatic iron overload characterized by high serum 
ferritin levels, normal serum iron, and associated metabolic 
abnormalities [32–35]. IR-HIO is detected in one-third to half 
of patients with NAFLD [31,32]. It is important to note that hy-
perferritinemia in patients with NAFLD and/or the MS overesti-
mates the degree of iron overload compared to hemochroma-
tosis. It is assumed that in NAFLD patients, the iron overload, 
characterized by mild degree of body iron excess compared 
to often markedly elevated serum ferritin levels, is a conse-
quence of a combination of alimentary and inflammatory driv-
en iron loading and retention [31]. Thus, elevated ferritin may 
be found in the MS without evidence of iron excess [9]. The 
origin of excess iron in NAFLD is still uncertain. Insulin was 
suggested to cause increased liver iron uptake due to its abil-
ity to redistribute transferrin receptors from an intracellular 
membrane compartment to the cell surface [31,32,36]. The 
first report of an impact of iron stores in non-hemochromato-
tic metabolic diseases was described in 1981 by Sullivan [37]. 
He observed that postponed occurrence of cardiovascular dis-
eases in women compared to men and the subsequent post-
menopausal increase could be caused by low premenopausal 
iron stores [31,37]. The association of higher iron store with 
several clinical manifestations of IR and MS has been repeat-
edly confirmed in other studies [9,38]. Moreover, iron over-
load can worsen IR by interfering with insulin receptor sig-
naling and inhibiting the ability to burn carbohydrates in the 
liver and muscle. It is well documented that liver and periph-
eral IR increase and pancreatic insulin secretion decrease as 
level of body iron rises [9].
Some authors found an association of iron with more pro-
gressed stages or higher incidence of NAFLD. In the study by 
Kowdley et al. [39], iron deposition in NAFLD liver biopsies was 
associated with more advanced stages of fibrosis and disease 
severity. Additionally, excess liver iron may also be involved 
in the pathogenesis of hepatocellular carcinoma in NASH pa-
tients [9]. Recently, Meli et al. [40] reported early impairment 
of iron metabolism in the initial stage of steatosis that con-
tributes to disease progression. They hypothesized that the 
concept of “multiple hits” in the progression of inflammation 
in NAFLD patients might include the early alteration of iron 
metabolism. In summary, the prevailing body of evidence sug-
gests that excess iron is a contributing factor for progression 
Liver disease Ferritin Serum iron TfS Hepcidin M Parenchyma
ALD �� �,�� �,�� ¯ + +
NAFLD � ↔ �, ↔ � – +
HCV �, ↔ �, ↔ �, ↔ ¯ – +
Table 1. The characteristics of iron distribution disorders.
ALD – alcoholic liver disease; NAFLD – nonalcoholic fatty liver disease; HCV – hepatitis C virus infection; TfS – transferrin saturation; 
M – macrophages – spleen, bone marrow, liver Kupffer cells; � – elevated; �� – markedly elevated; ↔ – unchanged; ¯ – decreased); 
+ present; – absent.
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of steatosis to NASH, cirrhosis, or liver carcinoma. Besides di-
rectly inducing liver damage, excess iron is involved in the 
pathogenesis of MS by inducing adipose tissue IR and modi-
fying the release of adipokines [41]. Interestingly, iron removal 
was found to improve coronary vascular dysfunction and endo-
thelial function in patients with diabetes and coronary artery 
disease with hemochromatosis. These findings are important, 
considering the recent observations regarding the increased 
cardiovascular morbidity and mortality in NAFLD patients [31].
Recent research has underlined the role of hepcidin in NAFLD. 
Increased adipose tissue expression of hepcidin is associated 
with inflammation in obese individuals, independent of ste-
atosis and nonalcoholic steatohepatitis (NASH). Furthermore, 
leptin expression is correlated with hepcidin levels in obese 
children and appears to enhance hepcidin mRNA expression 
in vitro. Additionally, leptin was found to up-regulate hepcidin 
transcription in hepatocyte cultures via JAK2/STAT3-dependent 
signaling pathways. Therefore, leptin-induced hepcidin syn-
thesis may favor iron perturbations in NAFLD patients [9,42]. 
On the other hand, necrosis can lead to iron leakage, which, 
in combination with phagocytosis by liver macrophages and 
increased levels of hepcidin (induced by inflammatory cyto-
kines), results in iron accumulation in Kupffer’s cells. Moreover, 
an in vivo study reported a highly significant correlation in pa-
tients with DIOS between hepcidin levels and TNF-alfa, indi-
cating that proinflammatory milieus also contribute to hep-
cidin production in NAFLD patients. From the clinical point of 
view, in NAFLD patients increased hepcidin and proinflamma-
tory cytokines can be derived from adipose tissue and the liv-
er [9,43]. Mesenchymal iron deposition is more common than 
hepatocellular iron accumulation, but usually both compart-
ments are affected. This is in contrast to tissue iron deposition 
in hemochromatosis, in which the iron is almost exclusively 
found in the hepatocellular compartment and macrophages 
are iron deficient [31]. Similar to the mechanism described 
for ALD, hepcidin downregulation may be a consequence of 
oxidative stress [5,11,32–35,44]. In NAFLD patients with liv-
er iron on histology, the duodenal iron exporter ferroportin is 
lower in comparison to NAFLD patients without liver iron ac-
cumulation and controls [45]. In summary, both iron and in-
flammation contribute to hepcidin synthesis in NAFLD patients.
Hepatitis C virus infection
Approximately 170 million people worldwide are infected with 
hepatitis C virus [46]. Infection with HCV is often asymptom-
atic, but can lead to severe liver damage. The pathogenesis 
of HCV infection is not yet fully understood, but according to 
research data, a chronic inflammation state and excess iron 
play an important role in the pathogenesis of chronic hepati-
tis C, as well as in the hepatocarcinogenesis [46,47]. For ex-
ample, Kato et al. [48] found that phlebotomy procedures are 
associated with lower risk of progression to hepatocellular car-
cinoma in patients affected with chronic hepatitis C virus infec-
tion. This data indicate a critical role of iron in hepatocellular 
carcinoma in patients with HCV [46]. However, the mecha-
nisms linking hepatic iron overload with disease progression 
and its contribution to hepatocarcinogenesis in chronic hepa-
titis C are not fully understood [46]. Iron accumulation in the 
liver and iron overload have been found mainly in patients in-
fected with HCV rather than in those infected with other types 
of viral hepatitis. It has been showed that about 30–40% of 
HCV patients have elevated serum iron and ferritin, as well as 
transferrin saturation (Table 1) [49,50]. According to the lit-
erature, hepatic iron content in patients with HCV is approx-
imately 2–5 times the normal hepatic iron content if the liv-
er weight is estimated to be 1500 g, which is much less than 
in hereditary hemochromatosis [46,50]. It is unclear whether 
iron predominantly accumulates in hepatocytes or the retic-
uloendothelial system (Kupffer cells) in HCV patients. Some 
authors have reported that iron was mainly localized in the 
Kupffer cells, whereas others reported its localization in hepa-
tocytes [46,51,52]. However, iron accumulation in hepatocytes 
can indicate potential DNA damage and genetic instability in 
association with HCV-induced oxidative stress. On the other 
hand, iron deposition in Kupffer cells can contribute to cyto-
kine release, leading to inflammation or fibrosis [46]. Recent 
findings have highlighted that hepcidin transcription is sup-
pressed in the presence of HCV infection. HCV decreases hep-
cidin levels through histone acetylation. The HCV core protein 
induces the production of reactive oxygen species, increas-
es hepatic expression of CCAAT/enhancer-binding protein (C/
EBP) homology protein (CHOP), and subsequently reduces DNA 
binding activity of C/EBPa, which leads to reduction of hepci-
din transcription. Consequently, decreased hepcidin expression 
increases ferroportin expression in the enterocytes and retic-
uloendothelial macrophages, resulting in increased duodenal 
iron transport and macrophage iron release, which lead to liv-
er iron accumulation. Additionally, inflammation can also have 
the opposing effects of stimulation and suppression of hep-
cidin transcription through the interleukin (IL)-6/signal trans-
ducer and activator of transcription (STAT) pathway and reac-
tive oxygen species pathway, respectively. In summary, relative 
suppression of hepcidin expression is a possible a mechanism 
responsible for the hepatic iron accumulation in patients with 
HCV [46]. Researchers have also found that hepcidin attenu-
ates HCV expression and reduces HCV replication in cell cul-
tures via STAT3 activation. STAT3 itself is involved in hepci-
din regulation; this suggests that a positive feedback system 
boosts the antiviral effects of hepcidin. In chronic HCV infec-
tion, hepatic steatosis is correlated with higher serum iron con-
centrations and transferrin saturation [53,54]. The hypothesis 
for this finding is that iron and HCV work together to cause fi-
brosis. Interestingly, recent studies have shown an improved 
clinical response in patients who were treated with combined 
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phlebotomy and interferon monotherapy compared to those 
treated with interferon alone. Other recent studies indicate that 
iron reduction maintained over several years results in histo-
pathological improvement and reduced risk of HCC [55,56].
Autoimmune liver diseases
Very recently, Lyberopoulou et al.  [57] published about a study 
on liver hepcidin gene expression, serum hepcidin levels, and 
hepcidin/ferritin ratios in patients with various chronic liver 
diseases, and including for the first time patients with auto-
immune liver disorders. They correlated these measurements 
with the clinical, histological, and laboratory data of their pa-
tients. In their analysis both serum hepcidin and the serum 
hepcidin/ferritin ratio were significantly lower in autoimmune 
hepatitis patients and patients with autoimmune cholestatic 
diseases (primary biliary cirrhosis and primary sclerosing chol-
angitis) compared to patients with chronic hepatitis B and C vi-
rus infection and compared to those with NAFLD, and correlat-
ed negatively with serum alkaline phosphatase levels. Patients 
with autoimmune hepatitis and those with autoimmune cho-
lestatic diseases maintained low serum hepcidin during the 
course of their 2-year treatment. The authors concluded that 
parallel determination of hepcidin expression levels in liver bi-
opsies and sera of patients with different liver diseases has 
revealed that serum hepcidin levels and their corresponding 
ratios to ferritin are lower in patients with autoimmune liver 
diseases in comparison to other investigated liver diseases [57].
Oxidative Stress and Iron Deposit Placement
The liver is the main organ affected by the oxidative stress 
caused by iron-overload toxicity. When transferrin saturation is 
increased by more than 75%, NTBI begins to accumulate [54]. 
NTBI is potentially toxic due to its high propensity to induce 
reactive oxygen species (ROS), and it can cause cellular dam-
age both at the plasma level and in intracellular organelles. 
Liver injury during iron overload may be caused by NTBI and 
iron deposits [58,59].
ROS are normally produced by metabolic functions in the cell. 
Iron, in conjunction with ROS, leads to an increase in hydroxyl 
radicals and, consequently, cellular damage. Through Haber-
Weiss and Fenton reactions, iron generates ROS [59,60]. The 
reduction of ferric iron to ferrous iron is mediated by the super-
oxide radical, which then reacts with hydrogen to form highly 
reactive hydroxyl radicals. Hydroxyl radicals cause an increase 
in phospholipid peroxidation, oxidation of amino acid side 
chains, DNA strand breaks, and protein fragmentation [10,61].
Iron deposits are localized in 1 of 3 possible histological pat-
terns: hepatocellular (HC) or parenchymal, reticuloendothelial 
system cells (RES), or mesenchymal and mixed RES/HC. In ear-
ly HH, iron is localized within hepatocytes and distributed in 
a decreasing gradient from the periportal to the centrolobu-
lar areas. This represents a typical parenchymal iron overload 
pattern. With time, periportal sideronecrosis occurs, resulting 
in macrophage activation followed by fibrosis and the redistri-
bution of iron to non-parenchymal cells. Iron accumulation in 
patients with DIOS and ALD is characterized by a mixed RES/
HC pattern and is associated with milder iron overload [62,63]. 
During HCV infection, iron deposits are found mostly in mes-
enchymal and endothelial cells. Iron deposits in patients with 
HCV infection are associated with activation of hepatic stel-
late cells, leading to their proliferation and differentiation into 
myofibroblast-like cells. This process results in liver damage 
[64,65]. Research by Nelson et al. identified a relationship be-
tween the placement of hepatic iron deposits and the histolog-
ical severity of NAFLD. According to Nelson et al., percentages 
of advanced fibrosis, portal inflammation, hepatocellular bal-
looning, and definitive NASH were higher in histological sam-
ples with an RES iron-staining pattern [63].
Future Perspectives
To date, iron overload has been treated with phlebotomy and 
iron chelators. Disadvantages of phlebotomy are concurrent 
anemias, difficulties for people with poor vascular access, ad-
verse physiological response to phlebotomy, fear, religious 
beliefs, and lack of long-term convenient access to phleboto-
my centers. Iron chelators have multiple adverse effects, and 
compliance is often suboptimal. Hepcidin deficiency plays a 
key role in iron overload; thus, influencing hepcidin produc-
tion or administering hepcidin substitutes could result in im-
proved treatment of conditions resulting in iron overload [8].
Recent discoveries have yielded promising results. Problems 
associated with the use of natural hepcidin have been obvi-
ated by the use of synthetic minihepcidins. Minihepcidins are 
small peptides that mimic hepcidin activity and have been 
used to ameliorate iron overload in mice. Natural hepcidin is 
expensive and has unfavorable pharmacological properties. 
Bioactive hepcidin has 4 disulfide bonds, and a high dosage 
is required for optimal therapeutic effects, which would make 
therapy with these molecules costly. From a pharmacological 
perspective, natural hepcidin has a short half-life due to rap-
id kidney excretion and a low per oral absorption because of 
its large size. By contrast, minihepcidins are small peptides of 
7–9 amino acids, which can be administered orally. They were 
rationally designed based on the region of hepcidin that inter-
acts with ferroportin. Experiments conducted on mouse mod-
els of HH showed a significant decrease in iron load after in-
traperitoneal injections of minihepcidin. Redistribution of iron 
from the liver to the spleen and macrophages was observed. 
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Unlike hepatocytes, macrophages are relatively resistant to 
iron-related oxidative stress [8,66].
Another therapeutic approach is to potentiate endogenous 
hepcidin production. Two tactics that have been explored are 
inactivation of TMPRSS6 and administration of BMP6 agonists. 
Inactivation of TMPRSS6 has thus far been accomplished ei-
ther via antisense oligonucleotides (ASOs) or small interfer-
ing RNAs (siRNAs). ASOs trigger the degradation of their tar-
get mRNA based on the RnaseH mechanism, while siRNAs 
inhibit expression of target genes through the RNA interfer-
ence pathway. Experiments on mice yielded positive results 
with both approaches. BMP6 agonists are associated with in-
creased BMP signaling and consequently increased hepcidin ex-
pression. However, peritoneal calcification has been observed 
in experimental models. Researchers are now shifting their fo-
cus to BMP type I receptor inhibitors (e.g., LDN-193189) and 
soluble forms of ALK3 (e.g., ALK3-Fc), which could be used to 
treat microcytic anemia by preventing increased hepcidin ex-
pression [8,16,67].
Conclusions
Iron homeostasis is crucial for normal functioning in humans. 
The liver plays a critical role in the regulation of iron levels, 
particularly through production of hepcidin. In patients with 
chronic liver disease, iron metabolism changes result in iron 
overload. This is believed to occur mostly due to low levels of 
hepcidin. Iron deposits and NTBI are responsible for further 
damage to the liver by inflicting oxidative stress on hepato-
cytes. These findings suggest that future studies should fo-
cus on the production of the hepcidin agonists minihepcidins 
and on manipulating various metabolic pathways to increase 
endogenous production of hepcidin.
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